Dyadic International Inc (DYAI): Net Income
-$7.36M
Year ended 2025-12-31
-$7.62M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$7.36M | n/m | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | -$5.81M | n/m | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | -$6.80M | n/m | 2025-03-26, From 2023-01-01 |
| 2022-12-31 | -$9.74M | n/m | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | -$13.07M | n/m | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | -$9.33M | n/m | 2022-03-29, From 2020-01-01 |
| 2019-12-31 | -$8.31M | n/m | 2021-03-30, From 2019-01-01 |
| 2018-12-31 | -$5.69M | n/m | 2020-03-30, From 2018-01-01 |
| 2017-12-31 | -$2.14M | n/a | 2019-03-27, From 2017-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Dyadic International Inc (DYAI) | 2025-12-31 | -$7.36M | n/m |
| Surrozen, Inc. (SRZN) | 2025-12-31 | -$242.03M | n/m |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | -$581.60M | n/m |
| CG Oncology, Inc. (CGON) | 2025-12-31 | -$161.00M | n/m |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | -$24.19M | n/m |
| Ocugen, Inc. (OCGN) | 2025-12-31 | -$67.85M | n/m |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | -$201.14M | n/m |
| Humacyte, Inc. (HUMA) | 2025-12-31 | -$40.83M | n/m |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | -$5.52M | n/m |
Compare DYAI, SRZN, CRSP, CGON side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗